Thursday, January 19, 2023
| 7:00 AM-8:00 AM | Complimentary Continental Breakfast |
| 7:00 AM-5:45 PM | Exhibits Open |
| 7:50 AM-9:30 AM | Controversies in Early-Stage Gastric and Esophageal Cancers
Welcome of the Day 20th Anniversary Opening Remarks Expanded Indications of Endoscopic Therapy Access to Care for Gastroesophageal Cancer Patient-Reported Outcomes and Quality of Life After Esophagectomy Moderated Panel Discussion |
| 10:00 AM-11:00 AM | Other Targets in Metastatic Esophageal and Gastric Cancers
Theranostics Organoid Versus PDX for Advanced Disease Other Targeted Therapy Case Panel: Oligometastatic Disease Moderated Panel Discussion |
| 11:15 AM-12:00 PM | Rapid Abstract Session A: Cancers of the Esophagus and Stomach |
| 11:15 AM-12:00 PM | Breakout Session: Managing Complications Across Treatment Modalities
Minimizing Complications Associated with Gastrectomy Minimizing the Side Effects of Radiation Minimizing Gastrointestinal Side Effects of Immunotherapy Moderated Panel Discussion |
| 12:00 PM-1:30 PM | Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
With Complimentary Boxed Lunch |
| 12:00 PM-1:30 PM | Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
With Complimentary Boxed Lunch |
| 12:15 PM-1:15 PM | Trainee and Early-Career Networking Luncheon |
| 1:30 PM-3:00 PM | Oral Abstract Session A: Cancers of the Esophagus and Stomach |
| 3:30 PM-4:45 PM | Integration of Immunotherapy Across All Lines of Treatment
How Do We Incorporate Immunotherapy for MSI-H Localized GI Cancers? Utilization of Immune Biomarkers and TMB in Clinical Practice A Look at Novel Immune Therapies in GI Cancers: What’s Coming? Moderated Panel Discussion |
| 4:45 PM-5:45 PM | Poster Session A (Continued) with Complimentary Wine and Cheese Reception |
| 4:45 PM-5:45 PM | Trials in Progress Poster Session A (Continued) with Complimentary Wine and Cheese Reception |
| 5:00 PM-5:45 PM | Poster Walks: Esophageal and Gastric Cancer and Other GI Cancers |
Friday, January 20, 2023
| 6:30 AM-7:55 AM | Complimentary Continental Breakfast |
| 7:00 AM-5:30 PM | Exhibits Open |
| 7:00 AM-7:45 AM | Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
| 7:00 AM-7:45 AM | Breakout Session: Pushing the Envelope in Transplant Oncology
Debate: Liver Transplantation for Intrahepatic CCA and Metastatic Colorectal Cancer: Are We There Yet?–FOR Debate: Liver Transplantation for Intrahepatic CCA and Metastatic Colorectal Cancer: Are We There Yet?–AGAINST Rebuttals and Questions from Moderators Moderated Panel Discussion |
| 8:15 AM-9:30 AM | Targeting the Tumor Microenvironment to Overcome Immune Resistance: Strategies and Future Directions
Welcome of the Day Immunology for the Clinician: Understanding the Basics Preclinical Mechanistic Strategies in Immuno-Oncology Modulation Macrophage Targeting in GI Cancers Panel Question and Answer |
| 10:00 AM-11:00 AM | Imaging and Therapy of NETS
Functional Imaging and PRRT: Practical Considerations and Future Directions Updates on Systemic Therapies Panel Discussion: Management of Local-Regional Therapies Panel Question and Answer |
| 11:15 AM-12:00 PM | Keynote
AI in Oncology Question and Answer |
| 12:00 PM-1:30 PM | Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Boxed Lunch |
| 12:00 PM-1:30 PM | Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Boxed Lunch |
| 12:15 PM-1:15 PM | Meet the Experts Networking Luncheon |
| 1:30 PM-3:00 PM | Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
| 3:30 PM-4:30 PM | Homologous Recombination Deficiency in Pancreaticobiliary Cancers
Beyond PARP Inhibitors Genetic Risk in Biliary Tract Cancer Immuno-Oncology Combinations Moderated Panel Discussion |
| 4:30 PM-5:30 PM | Poster Session B (Continued) With Wine and Cheese Reception |
| 4:30 PM-5:30 PM | Trials in Progress Session B (Continued) With Wine and Cheese Reception |
| 4:45 PM-5:30 PM | Poster Walks: Hepatobiliary Cancer, Pancreatic Cancer, Small Bowel Cancer, and Neuroendocrine/Carcinoid |
| 4:45 PM-5:30 PM | Women’s Networking Reception |
Saturday, January 21, 2023
| 6:30 AM-7:55 AM | Poster Session C: Cancers of the Colon, Rectum, and Anus
With Complimentary Continental Breakfast |
| 6:30 AM-7:55 AM | Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
With Complimentary Continental Breakfast |
| 7:00 AM-7:45 AM | Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus |
| 7:00 AM-7:45 AM | Breakout Session: Germline Genetic Testing in Colorectal Cancer: Should It Be Performed Universally?
Introduction Debate: Germline Genetic Testing Should be Performed Universally–FOR Debate: Germline Genetic Testing Should be Performed Universally–AGAINST Moderated Panel Discussion |
| 8:10 AM-9:30 AM | Circulating Tumor DNA: Prime Time or Jumping Too Soon?
Welcome of the Day Adjuvant Therapy in Colon Cancer Metastatic Pancreaticobiliary and Gastroesophageal Cancer Moderated Panel Discussion |
| 9:45 AM-10:30 AM | Keynote
Equitable Solutions for Reducing Excess Mortality in Minority Populations Question and Answer |
| 11:00 AM-12:30 PM | Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus |
| 12:30 PM-2:00 PM | Poster Session C (Continued) With Complimentary Boxed Lunch |
| 12:30 PM-2:00 PM | Trials in Progress Poster Session C (Continued) With Complimentary Boxed Lunch |
| 12:45 PM-1:30 PM | Poster Walks: Anal Cancer and Colorectal Cancer |
| 2:00 PM-3:00 PM | State of the Art Non-operative Management of Rectal Cancer
Radiologic Biomarkers to Select Patients A Surgical Viewpoint: When to Bring out the Scalpel Intensifying or Substituting Chemotherapy to Maximize Eligible Patients: MMR Status Matters Moderated Panel Discussion |
| 3:15 PM-4:15 PM | Refinement of Metastatic Colorectal Cancer Management
Debate: For a Fit Patient with Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, First-Line EGFR Antibody Is an Essential Treatment–FOR Debate: For a Fit Patient with Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, First-Line EGFR Antibody Is an Essential Treatment–AGAINST Intensifying Chemotherapy in mCRC: What, When, and How? Tumor Board: Management of Recurrence after Hepatic Surgery Moderated Panel Discussion |
For more information: https://conferences.asco.org/gi/program
